StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report report published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The stock has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.
Genocea Biosciences Company Profile
Recommended Stories
- Five stocks we like better than Genocea Biosciences
- How to Effectively Use the MarketBeat Ratings Screener
- High-Yield Texas Instruments Could Hit New Highs Soon
- Ride Out The Recession With These Dividend Kings
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Most active stocks: Dollar volume vs share volume
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.